Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Undergraduate School

Bachelor of Science

University of North Carolina

Chapel Hill, NC

Graduate School

Biological Sciences

University of California, San Francisco

San Francisco, CA

Medical School

University of California, Los Angeles

Los Angeles, CA

Internship

Pediatrics

Boston Children's Hospital/Boston Medical Center

Boston, MA

Residency

Pediatrics

Boston Children's Hospital/Boston Medical Center

Boston, MA

Fellowship

Pediatric Hematology -Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

Certifications

  • American Board of Pediatrics (General)

Publications

  1. The dynamics of hematopoiesis over the human lifespan. Nat Methods. 2025 Feb; 22(2):422-434. View Abstract

  2. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024 06 25; 8(12):3001-3012. View Abstract

  3. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nat Commun. 2024 Apr 18; 15(1):3258. View Abstract

  4. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Abstract

  5. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023 10 12; 142(15):1281-1296. View Abstract

  6. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 08 22; 7(16):4647-4657. View Abstract

  7. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 May 24. View Abstract

  8. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022 11 08; 6(21):5786-5796. View Abstract

  9. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease. Front Immunol. 2022; 13:954966. View Abstract

  10. Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency. Bone Marrow Transplant. 2022 11; 57(11):1721-1723. View Abstract

  11. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022 08 09; 6(15):4392-4402. View Abstract

  12. Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients. Contemp Clin Trials. 2022 09; 120:106849. View Abstract

  13. Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Transplant Cell Ther. 2022 08; 28(8):502.e1-502.e12. View Abstract

  14. Genetic diagnosis of immune dysregulation can lead to targeted therapy for interstitial lung disease: A case series and single center approach. Pediatr Pulmonol. 2022 07; 57(7):1577-1587. View Abstract

  15. Spontaneous resolution of severe idiopathic T cell lymphopenia. Clin Immunol. 2022 05; 238:109014. View Abstract

  16. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight. 2022 04 08; 7(7). View Abstract

  17. Hematopoietic Stem Cell Transplantation Is a Curative Therapy for Transferrin Receptor 1 (TFRC) Deficiency. J Allergy Clin Immunol Pract. 2021 02; 9(2):753-759.e2. View Abstract

  18. The role of regulatory T cells in graft-versus-host disease management. Expert Rev Hematol. 2020 02; 13(2):141-154. View Abstract

  19. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561. View Abstract

  20. TGFß signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 06 18; 129(9):3821-3826. View Abstract

  21. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979. View Abstract

  22. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994. View Abstract

  23. Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease. Front Oncol. 2019; 9:141. View Abstract

  24. Immunologic reconstitution following hematopoietic stem cell transplantation despite lymph node paucity in NF-?B-inducing kinase deficiency. J Allergy Clin Immunol. 2019 03; 143(3):1240-1243.e4. View Abstract

  25. B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood. 2018 06 28; 131(26):2967-2977. View Abstract

  26. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. 2018 07; 24(7):1322-1340. View Abstract

  27. SID-1 Domains Important for dsRNA Import in Caenorhabditis elegans. G3 (Bethesda). 2017 12 04; 7(12):3887-3899. View Abstract

  28. Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. Clin Immunol. 2017 10; 183:142-144. View Abstract

  29. Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278. View Abstract

  30. Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Feb; 52(2):183-190. View Abstract

  31. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7. View Abstract

  32. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57. View Abstract

  33. Apoptosis Triggers Specific, Rapid, and Global mRNA Decay with 3' Uridylated Intermediates Degraded by DIS3L2. Cell Rep. 2015 May 19; 11(7):1079-89. View Abstract

  34. Leukocyte protease binding to nucleic acids promotes nuclear localization and cleavage of nucleic acid binding proteins. J Immunol. 2014 Jun 01; 192(11):5390-7. View Abstract

  35. Environmental RNA interference. Trends Genet. 2008 Jun; 24(6):297-305. View Abstract

  36. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 2006 May; 9(5):405-16. View Abstract

  37. Identification of genes that regulate a left-right asymmetric neuronal migration in Caenorhabditis elegans. Genetics. 2003 Aug; 164(4):1355-67. View Abstract

  38. Multiple levels of regulation specify the polarity of an asymmetric cell division in C. elegans. Development. 2000 Nov; 127(21):4587-98. View Abstract

  39. A Wnt signaling system that specifies two patterns of cell migration in C. elegans. Mol Cell. 1999 Nov; 4(5):851-8. View Abstract

  40. A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Development. 1999 Jan; 126(1):37-49. View Abstract
BESbswy